Arrowhead Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 525
- Market Cap
- $2.9B
- Introduction
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Ste...
A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)
- Conditions
- Interventions
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT02797522
- Locations
- 🇳🇿
Auckland Clinical Studies Ltd, Grafton, Auckland, New Zealand
Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection
- Conditions
- Interventions
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT02738008
- Locations
- 🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇨🇳Queen Mary Hospital, Hong Kong, China
🇩🇪Eugastro Gmbh, Leipzig, Germany
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT02604212
- Locations
- 🇩🇪
Universitaetsklinikum Leipzig, Leipzig, Germany
🇩🇪Universitaetsklinikum Wuerzburg, Medizinische Klinik Und Poliklinik II, Wuerzburg, Germany
🇩🇪Medizinische Hochschule Hannover, Hannover, Germany
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
- Conditions
- Interventions
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT02604199
- Locations
- 🇰🇷
Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
🇩🇪Eugastro Gmbh, Leipzig, Germany
🇩🇪University Hospital of Tuebingen, Tuebingen, Germany
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
- Conditions
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 79
- Registration Number
- NCT02577029
- Locations
- 🇦🇺
St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺Concord Repatriation General Hospital, Gastroenterology & Liver Services, Concord, New South Wales, Australia
A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT02535416
- Locations
- 🇦🇺
QPharm, Pty Limited, Royal Brisbane Hospital, Herston, Queensland, Australia
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
- Conditions
- Interventions
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT02452528
- Locations
- 🇺🇸
Kaiser Permanente, San Francisco, California, United States
🇺🇸Ichan School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Univ. Of Miami School Of Medicine/Center For Liver Diseases, Miami, Florida, United States
A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)
- Conditions
- Interventions
- First Posted Date
- 2015-02-16
- Last Posted Date
- 2018-08-03
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 65
- Registration Number
- NCT02363946
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
🇦🇺Nucleus Network Ltd, Melbourne, Victoria, Australia
🇩🇪Universitatsklinikum des Saarlandes, Homburg, Germany
Study of ARC-520 in Patient With Chronic Hepatitis B Virus
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Registration Number
- NCT02349126
- Locations
- 🇦🇺
Nucleus Network Ltd, Melbourne, Victoria, Australia
A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
- Conditions
- Interventions
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT02065336
- Locations
- 🇭🇰
Prince of Wales Hospital, Shatin, Hong Kong
🇭🇰Queen Mary Hospital, Pokfulam, Hong Kong